Alivus Life Sciences to acquire 76% of IQGEN-X Pharma Private Limited
Alivus Life Sciences (BSE: ALIVUS) said it has agreed a deal to acquire 76% of IQGEN-X Pharma Private Limited. The company is valued at about ₹17,862 crore.
What happened
Alivus Life Sciences (BSE: ALIVUS) informed the stock exchanges on 11 November 2026 at 06:28 PM that it has agreed a deal to acquire 76% of IQGEN-X Pharma Private Limited.
From the filing: "We refer to our letter dated August 18, 2026 in relation to share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited ("IQGEN-X")."
Company snapshot
Alivus Life Sciences is a small-cap company in the Healthcare sector, with a market value of about ₹17,862 crore.
The stock last traded at ₹1,454.9, against a 52-week range of ₹819–₹1,554 (6.4% below the high).
Before this filing the shares had moved +10.3% over the month and +7.3% over three months. Average daily turnover over the last 20 sessions was about ₹47.7 crore.
Promoters held 74.85% at the end of Q2 FY27, down 0.02% points from the previous quarter. Foreign institutions owned 5.93% and domestic institutions 7.03%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 588 | 130 | 10.6 |
| Q3 FY26 | 673 | 150.3 | 12.25 |
| Q4 FY26 | 689 | 162.7 | 13.23 |
| Q1 FY27 | 640 | 160.1 | 13.04 |
| Q2 FY27 | 682 | 196.7 | 16.02 |
What history shows
This is not the company's first m&a disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
Across 168 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.2% over five days; 60% of them rose the next day.
Market-wide, 2,435 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
- Alivus Life Sciences Ltd (BOM:543322) (Q2 2027) Earnings Call Highlights: Margin Surge, CDMO ...
- Alivus Life Sciences executes shareholders agreement with IQGEN-X Pharma
- Block Deals: SoftBank sells Rs 1,896 crore worth of Lenskart shares; Alivus Life Sciences promoter...
- Alivus Life Sciences block deal: Promoter Nirma sells over 28 lakh shares worth Rs 390 crore; Norges Bank,
- Alivus Life Sciences Q2 FY27 Profit Rises 51.3%
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.